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Constitutively activated prosurvival pathways render cancer cells addicted to their effects. Consequently they turn out to be the
Achilles’ heels whose inhibition can be exploited in anticancer therapy. Primary effusion lymphomas (PELs) are very aggressive
non-Hodgkin’s B cell lymphomas, whose pathogenesis is strictly linked to Kaposi’s sarcoma herpesvirus (KSHV) infection. Here we
summarized previous studies fromour and other laboratories exploring the cytotoxic effect of drugs inhibiting themain prosurvival
pathways activated in PEL cells. Moreover, the immunogenicity of cell death, in terms of dendritic cell (DC) activation and their
potential side effect on DCs, is discussed.
1. Primary Effusion Lymphomas’ Biology
Primary effusion lymphomas (PELs) are very aggressive non-
Hodgkin’s B cell lymphomas with poor prognosis that fre-
quently arise in immune-compromised patients [1]. PELs
originate from postgerminal center B cells and exhibit inde-
terminate immune-phenotypes; that is, they express CD45,
CD138, and activation-associated antigens (CD30, CD38, and
HLA-DR) and lack surface expression of B cell markers
(CD19, CD20, CD79a, and immunoglobulin) but exhibit
clonal rearrangements and somatic hypermutation of the
immunoglobulin genes. PELs are strictly associated with a
DNA oncovirus, the Kaposi’s sarcoma herpesvirus (KSHV),
and, in the majority of cases, they are dually infected by a
second oncovirus belonging to the gamma-herpesvirus fam-
ily [2, 3], the Epstein-Barr virus (EBV) [4]. The low response
to conventional therapies indicates that new therapeutic stra-
tegies are needed for PELs. PEL tumor growth relays on the
presence of cytokines that, produced by the tumor itself [5],
stimulate their own release with an autocrine positive feed-
back loop. An important role in PEL survival has been
reported for interleukin- (IL-) 6, IL-10, vascular endothelial
growth factor (VEGF), and Oncostatin M [6–8]. In addition
to cellular cytokines, KSHV encodes its own viral cytokines
such as IL-6 which is similar to human IL-6 and exerts an
important prosurvival effect on PEL cells [6, 9] and macro-
phage inhibitory proteins (MIPs) that affect the immune
system of the infected host [10].
2. Prosurvival Molecules in PELs
PEL cell survival relays on the constitutive activation of
several pathways and also on the hyperexpression of several
heat shock proteins (HSPs), a characteristic that is common
among the cancer cells.
2.1. JAK2/STAT3 Pathway. By engagement of their specific
cellular receptors, cytokines such as IL-6 and IL-10 and
VEGF activate the JAK2/STAT3 transduction pathway that
promotes the transcription of genes encoding for proteins
involved in PEL resistance to apoptosis and contributes to
tumor survival [11–13]. Consequently, the specific inhibition
of STAT3 activation by AG490 has been reported to induce
PEL cell death by downregulating survivin expression [14]. In
addition, we have recently reported that AG490 is able to trig-
ger an immunogenic apoptosis in PEL cells [15]. This aspect
is of pivotal importance since it is now clear enough that,
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without the contribution of the immune system, obtained
by triggering an immunogenic cell death type and/or the
reversion of the tumor induced immunosuppression [16], no
complete eradication of cancer can be achieved by anticancer
therapies [17, 18]. Moreover AG490 is able to revert immuno-
suppression caused by tumor-released factors or induced by
tumor viruses such as KSHV, which correlates with STAT3
activation in immune cells [19, 20].This immune-stimulating
AG490 property further encourages its use in PEL anticancer
therapy.
2.2. PI3K/AKT/mTOR Pathway. It is known that, in addi-
tion to STAT3, cytokines like IL-6 and IL-10, VEGF, and
Oncostatin M [21] are able to activate other pathways such
as PI3K/AKT and Ras/MAPK that govern fundamental
processes [22], such as cell proliferation, differentiation,
metabolism, and tumor survival. The PI3K/AKT is constitu-
tively activated in PELs due to the effect mediated by PEL
released cytokines and following KSHV infection [23], in
particular as an effect of K1 viral protein expression [24]. Pre-
vious papers have reported that targeting PI3K/AKT pathway
in PEL cellsmay represent an effective anticancer strategy [25,
26]. We have reported that KSHV infection hyperactivates
AKT in THP-1 cells and, as a consequence, the response to
proteasome inhibition is reduced. Moreover, AKT activation
also leads to Glut1 membrane localization, which is known to
promote cell survival by increasing the glucose uptake.On the
other hand, we found that Glut1 translocation renders THP-
1 cells more susceptible to the glycolysis inhibitor 2-deoxy-
D-glucose (DG) effect [27]. This is another example of how
a prosurvival effect turns out to be a prodeath effect in tumor
cells. Finally, since PI3K/AKT activation leads to the phos-
phorylation of the downstreammoleculemTOR, also its inhi-
bition has been exploited in PEL therapy [28]. mTOR inhibi-
tion has been shown to reduce PEL cell survival by interfering
with the release of cytokines known to be essential for
PEL cell growth, and more recently it has been shown that
mTOR inhibition can be effective also against a second
KSHV-associated malignancy such as Kaposi’s sarcoma.
2.3. MAPK Pathways. Mitogen activated protein kinases
(MAPKs) including ERKs, JNKs, and p38 kinases control a
vast array of physiological processes [29]. They can be
activated in tumor cells by several stimuli such as stress con-
ditions and inflammatory cytokines, also produced by tumor
itself. Their inhibition can be potentially explorable in PEL
therapy, considering that a cross-talk between these path-
ways and other prosurvival pathways, such as NF-𝜅B and
PI3K/AKT/m-TOR, has been reported [30]. In a recent study,
we have shown that JNK inhibition enhances Bortezomib-
induced cell death and that SP600125 JNK inhibitor is also
able to induce PEL cell death to some extent [31]. A prosur-
vival role of JNK2 activation during the ER stress caused by
tunicamycin treatment has also been shown in a different cell
type [32]. In addition, p38 MAPK seems to be activated in
PEL cells, in particular in those harbouring KSHV, in com-
parison with KSHV-negative PEL cells [4].
2.4. NF-𝜅B Pathway. An essential role in PEL cell survival is
known to be played by NF-𝜅B, constitutively activated in PEL
cells due also to the effect mediated by KSHV-encoded viral
FLICE-inhibitory protein (v-FLIP) expression [33, 34]. It has
been reported that NF-𝜅B inhibition with Bay11-7082 exerts a
strong reduction of PEL cell survival [33]. Moreover, the
Bortezomib cytotoxic effect, previously observed on PEL
cells, also involves NF-𝜅B inhibition [35], even if its main
cytotoxic effect is proteasome inhibition [36]. We have previ-
ously explored the immunogenicity of Bortezomib-induced
cell death in PEL and showed that Bortezomib was able to
induce damage associated molecular patterns (DAMPs)
expression on the surface of apoptotic PEL cells, which then
resulted in dendritic cell (DC) activation [15, 37]. Moreover,
we have demonstrated that Bortezomib induces endoplasmic
reticulum (ER) stress and a prosurvival autophagy in PEL
cells, due to the accumulation of ubiquitinated proteins
consequent to the inhibition of proteasomal degradation.The
autophagic blockage, during Bortezomib treatment, further
increased its cytotoxic effect. Thus this strategy could be
explored in the cancer therapy against PELs [31].
2.5.HSPs. A further effectmediated by the activation of path-
ways such as Ras/MAPK and JAK/STAT3 is the increase of
heat shock protein (HSP) expression [38, 39]. HSPs are
known to help cancer cells to survive in the stressful con-
ditions caused by their rapid growth and nutrient shortage.
HSPs also counteract the cytotoxic effects induced by
chemotherapeutic treatments. For this reason they represent
a target for anticancer therapy [38], also considering that their
expression, and consequently the cytotoxic effect of their
inhibition, is low in normal cells compared with can-
cer cells. Accordingly, we have recently reported that the
inhibition of HSP70, using the small molecule 2-pheny-
lethynesulfonamide (PES), is a successful therapeutic strategy
against PEL cells and that PES showed very low cytotoxic
effect on normal B cells from which PEL cells arise [40]. PES
induced lysosome permeabilization and a necroptotic cell
death type in PEL cells with immunogenic properties toward
DCs. It represents a valid strategy against this cancer and pos-
sibly against other tumors that, displaying oncosuppressor
mutations,may be resistant to apoptosis inducing drugs. Also
the inhibition of HSP90, another chaperone protein with the
essential function in protein correct folding, has been
reported to be effective against PELs [41, 42], as well as against
multiple myeloma, which shares many similarities with PELs
[43, 44].
3. Antiviral Strategies in PELs
PEL cells harbour KSHV, which persists in a latent state in the
majority of the cells. Upon appropriate stimuli, latent infec-
tion can be switched into lytic productive infection that gen-
erally leads to cell lysis and spread of the viral particles. The
possibility to kill tumor cells by inducing viral replication can
be explored in the therapy against tumors latently infected
with DNA viruses, especially because during viral replication
tumor cells become sensitive to the effects induced by the
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Figure 1: Effect of Bortezomib (BZ) (Santa Cruz) or Bay11-7082 (BAY) (Santa Cruz) on BC3 and BCBL1 PEL cells. (a) Effect on NF-𝜅B p65
nuclear localization of Bortezomib in BC3 cells, in comparison to the untreated control cells, analyzed by immunofluorescence assay (IFA).
A representative experiment out of three is shown. (b and c) Trypan blue exclusion assays of BC3 and BCBL1 PEL cells treated for 24 hours
with Bortezomib (BZ) or Bay11-7082 (BAY), at the indicated doses. The mean ± SD of three independent experiments is reported.
antiviral drugs. For the above reasons, strategies that allow
the manipulation of viral life cycle, reducing or promoting
viral production, are potentially explorable in PELs. One of
the strategies that allowmanipulating the viral life cycle is the
modulation of the cellular autophagy which has been shown
to have a strong impact on KSHV replication [45].
4. Experimental Data
Here we have summarized our and other experimental
evidences showing the cytotoxic effect mediated by the phar-
macological inhibition of all these pathways in PEL cell lines.
We first confirmed that indirectly inhibiting NF-𝜅B with
Bortezomib (Figure 1(a)) a dose-dependent reduction of PEL
cell survival can be observed (Figure 1(b)), confirming our
previous reported results [15]. Even stronger cytotoxic activ-
ity on PEL cells was obtained with Bay11-7082NF-𝜅B, specific
inhibitor [46], that was indeed able to kill themajority of PEL
cells at the concentration of 5mM (Figure 1(c)). Next, given
the importance of JAK2/STAT3 activation in PEL survival
and in the reversion of immunosuppression, reported by us as
well as by other groups [14, 15, 47], we performed a dose-
response assay pharmacologically inhibiting STAT3 activa-
tion with AG490 and confirmed that it was very effective in
reducing PEL cell survival. Besides its efficacy against PEL
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Figure 2: Effect on PEL cell cytotoxicity of p38, JNK, or ERK inhibition by SB203580, SP600125, and PD98059, respectively, based on trypan
blue exclusion is reported. The treatment was performed for 24 hours at the concentration of 10𝜇M. All the reagents were purchased from
Santa Cruz. The mean ± SD of three independent experiments is reported.
cells, the use of AG490 is also encouraged by our previous
observations showing that it can induce an immunogenic cell
death in these cells and has a low side effect on dendritic cell
viability [15, 38]. Next, a dose-response treatment aimed at
the targeting of PI3K/AKT pathway was then performedwith
AKT inhibitor LY294002 against BC3 and BCBL1 PEL cells.
LY294002, used at the concentration of 20mM, induced
about 50% reduction of PEL cell survival, after 24 hours of
treatment (Figure 2). One of the consequences of AKT
activation is a change in the cell metabolism, such as an
increase of cell resistance to glycolysis inhibitors.Thus, it will
be interesting to investigate how treatment LY294002 would
affect PEL cell resistance to glucose starvation. A low
cytotoxic effect on PEL cells was observed with rapamycin
mTOR inhibitor, used at 50 nM, for 24 hours. However, its
combination with autophagy inhibitor 3-methyladenine (3-
MA) resulted in a higher cytotoxic effect (unpublished data).
This is in agreement with the notion that inhibition of mTOR
induces autophagy that usually helps cells to survive during
starvation or stressful conditions; thus its inhibition may
increase cell death.
Additionally, the potential cytotoxic effect of the inhibi-
tion of JNK, p38, and ERK MAPK pathways was evaluated
on PEL cells. The results shown in Figure 3 indicate that the
higher cytotoxic effect was obtained by using SP600125 JNK
inhibitor, confirming that this pathway plays an important
prosurvival role in PEL cells, according to previously reported
studies [31]. All MAPK inhibitors were used at the concen-
tration of 10mM and a low cytotoxicity was also observed
with the inhibitor of p38 MAPK SB203580 and with the
ERK inhibitor PD98059, according to a recent study [48]
(Figure 3).
The activation of the above-mentioned prosurvival path-
way leads to upregulation of HSPs, which are classified based
on their molecular weight. They play multiple roles in cancer
cells; for example, they ensure the correct protein folding,
which is very important especially for cancer cells. More-
over, HSPs are required for the expression of some KSHV
essential proteins [49, 50]. The major role in cancer cell
survival is played by HSP70 and HSP90. The cytotoxicity of
HSP70 inhibitor 2-phenylethynesulfonamide (PES) against
PEL cells was previously reported by our group [40]. Here
we compared the effect of PES with Benzisoxazole HSP90
inhibitor, considering that HSP70, besides its chaperone
function, plays an important role in the maintenance of
the lysosome membrane stabilization. The results shown in
Figure 4 indicate that both HSP70 and HSP90 were essential
for PEL cell survival. Trypan blue exclusion was used in all
the dose-response cytotoxic assay performed in this study.
To further explore how cell death occurred in PEL cells
by the inhibition of the above-reported prosurvival pathways,
we then performed a western-blot analysis of the poly
(ADP-ribose) polymerase (PARP) cleavage. PARP cleavage
generally represents a final event of an apoptotic cell death
and is mainly mediated by caspase activation [51]. We found
that, except for PES, previously shown to induce a necroptotic
cell death type [40], all the other drugs utilized in this study
induced the cleavage of PARP in PEL cells (Figure 5). Besides
considering the cytotoxic effect, it is important to evaluate the
side effect that anticancer drugs could have on the immune
cells and DCs in particular, being cells with a pivotal role in
the immune system [52]. Preliminary data obtained by expos-
ing monocyte-derived DCs to all the drugs used against PEL
cells, at the concentrations able to reduce 50% of PEL cell
survival, showed that all of them, except for Bortezomib and
Bay11-7082, were almost completely safe towards DCs (data
not shown).
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Figure 3: Dose-response cytotoxic assay of STAT3 or AKT inhibition in BC3 and BCBL1 PEL cells treated with AG490 (AG) (Calbiochem)
or LY294002 (LY) (Santa Cruz), respectively, at the indicated doses. Trypan blue exclusion assays were performed after 24 hours of treatment.
Mean ± SD of three experiments is reported.
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Figure 4: Dose-response cytotoxic assay of BC3 and BCBL1 PEL cells treated with PES (HSP70 inhibitor) (Calbiochem) and Benzisoxazole
(BENZ) (HSP90 inhibitor) (Calbiochem), at the indicated doses. Trypan blue exclusion assays were performed after 24 hours of treatment
and mean ± SD of three independent experiments is reported.
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Figure 5: Western-blot analysis showing the PARP cleavage in
BCBL1 cells treated for 24 hourswith all the above reported cytotoxic
drugs: LY294002 (LY), SB203580 (SB), SP600125 (SP), PD98059
(PD), AG490 (AG), PES, and Benzisoxazole (BENZ). 𝛽-Actin is
included as loading control and a representative experiment out of
three is reported. Antibodies against PARP (Cell Signaling) and 𝛽-
actin (SigmaAldrich) were diluted 1 : 1000 and 1 : 10000, respectively.
5. Conclusion
In conclusion, the use of drugs that target constitutively acti-
vated pathways in PEL cells could represent a valid alternative
in translational therapies, especially considering the ability
of most of them to induce an immunogenic cell death. In
addition, their use is very promising because they have a
low side effect towards the immune cells, and DCs in partic-
ular, rendering their use safer than conventional chemother-
apies.
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